Compugen Ltd

Uždarymo kaina

2.12 -0.93

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.1

Max

2.17

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-65M

-7.7M

Pardavimai

-65M

2.2M

P/E

Sektoriaus vid.

5.5

56.269

Pelnas, tenkantis vienai akcijai

-0.08

Pelno marža

-352.436

Darbuotojai

75

EBITDA

-64M

-7.7M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+118.22% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-73M

198M

Ankstesnė atidarymo kaina

3.05

Ankstesnė uždarymo kaina

2.12

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-30 23:56; UTC

Ulta Beauty shares rose in after-market trading, though they remain below the 20-day moving average and near the lower end of their one-month range.

2026-06-30 23:56; UTC

Correlated Moves

After-market trading for the iShares Core U.S. Aggregate Bond ETF is roughly flat, reflecting routine performance amid slight gains in the US 2Y Treasury Bond.

2026-06-30 23:52; UTC

European equity indices rise as Germany's inflation falls below expectations, easing ECB tightening concerns, while Bitcoin declines amid market volatility.

2026-06-30 23:52; UTC

Global markets show mixed performance as European indices rise on tech optimism while U.S. stocks decline amid volatility, with the dollar strengthening against the yen and Bitcoin falling due to regulatory concerns.

2026-06-30 23:52; UTC

U.S. equity indices decline as tech stocks sell off, while European markets rise on positive economic data; dollar strengthens amid Fed rate hike expectations and Bitcoin drops 2.8%.

2026-06-30 23:52; UTC

Mixed Asia equity markets as Japan's optimism contrasts with U.S. profit-taking; Bitcoin declines amid shifting investor focus ahead of key U.S. employment data.

2026-06-30 23:52; UTC

Bank of Japan to release Q2 Tankan Index on June 30, with market expectations set at a stable 16.0 amid ongoing optimism in manufacturing sector.

2026-06-30 23:52; UTC

South Korea's Exports Expected to Surge Again Ahead of July 1 Release Amid Strong Semiconductor Demand and Positive Market Sentiment.

2026-06-30 23:52; UTC

South Korea's S&P Global Manufacturing PMI set for July 1, with positive trends expected amid regional growth signals and inflation concerns.

2026-06-30 23:52; UTC

ISM Manufacturing Employment Report Set for July 1: Market Eyes Mixed Economic Signals and Job Growth Ahead of Potential Fed Rate Hikes.

2026-06-30 23:52; UTC

Australia's Balance of Trade data set for July 2, 2026, anticipates a AUD 2.3 billion surplus amid mixed stock market sentiment and geopolitical concerns.

2026-06-30 23:52; UTC

ISM Manufacturing PMI for June 2026 set to release on July 1, forecasted at 54.0 amid cautious optimism and geopolitical tensions impacting market stability.

2026-06-30 23:52; UTC

Brazil's BCB Focus Market Readout on July 6, 2026, may signal interest rate adjustments amid mixed investor sentiment influenced by inflation and global market pressures.

2026-06-30 23:52; UTC

Brazil's Industrial Production Expected to Continue Growth Trend Ahead of July 2 Release Amid Record Oil Output from Petrobras

2026-06-30 23:52; UTC

Canada's Manufacturing PMI Release on July 2 Expected to Reflect Economic Resilience Amid Mixed Global Signals and Geopolitical Pressures.

2026-06-30 23:52; UTC

ECB Forum on Central Banking Set for July 2026 Amid Cautious Market Sentiment and Potential Changes to Interest Rates.

2026-06-30 23:52; UTC

Japan's Current Account Data Release on July 7, 2026, Expected to Reflect Economic Trends Amidst Cautious Investor Optimism.

2026-06-30 23:51; UTC

Correlated Moves
ETF Constituents

Vanguard FTSE Europe ETF is lower in after-market hours, influenced by mixed returns from holdings like BCS and NOK, as well as broader market sentiment.

2026-06-30 23:51; UTC

ETF Constituents

Vanguard Small-Cap ETF declines after hours, impacted by significant losses in holdings like SSTK, BLDR, and TOL. Trading activity remains weak.

2026-06-30 23:51; UTC

ETF Constituents

VanEck Gold Miners ETF declines in after-market trading, following three consecutive lower daily closes. KGC, AEM, and NEM all recorded negative returns.

2026-06-30 23:51; UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

2026-06-30 23:51; UTC

Texas Instruments Inc. shares are trading higher in after-market hours, reflecting broader positive momentum in equity indices amid optimism around economic data and AI investments.

2026-06-30 23:46; UTC

NetEase Inc. shares are higher in after-market trading, reflecting unusual strength following three consecutive sessions of gains amid a positive trend in European equities.

2026-06-30 23:46; UTC

Lululemon Athletica Inc shares are lower in after-market hours, remaining near the lower end of their one-month range and below the 20-day moving average.

2026-06-30 23:46; UTC

ETF Constituents

iShares MSCI South Korea ETF declines after market close, influenced by mixed global equity performance. LG Display saw a positive return, while SK Telecom had minimal impact.

2026-06-30 23:46; UTC

ETF Constituents

iShares China Large-Cap ETF advances in after-market trading, influenced by JD's negative contribution. FXI remains near the lower end of its one-month range.

2026-06-30 23:42; UTC

Australia's Ai Group Industry Index plunges to -30.0, signaling severe industrial contraction amid mixed economic signals and persistent challenges.

2026-06-30 23:42; UTC

MBA 30-Year Mortgage Rate Release on July 1 Expected to Show Stability Amid High Borrowing Costs and Mixed Consumer Confidence in Housing Market

2026-06-30 23:42; UTC

Mexican Business Confidence Remains Low at 47.5 Points Ahead of Key EMOE Report Amid Regulatory Changes and Economic Uncertainties

2026-06-30 23:42; UTC

Australia's Building Permits Expected to Rise 0.01% Amid Cautious Economic Sentiment and Mixed Market Indicators

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

118.22% į viršų

12 mėnesių prognozė

Vidutinis 4.67 USD  118.22%

Aukščiausias 5 USD

Žemiausias 4 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

3 ratings

3

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
help-icon Live chat